Beyond Insulin: How Immunotherapy Is Expanding Type 1 Diabetes Treatment Options

For decades, people with Type 1 diabetes have relied on insulin replacement and increasingly sophisticated delivery methods to manage their condition. This fall, that landscape shifted when teplizumab became the first drug approved specifically to delay the onset of Type 1 diabetes. In clinical trials, the drug demonstrated the ability to postpone disease onset by up to three to four years—a meaningful window that researchers hope could change how we approach Type 1 diabetes prevention and early management.

The approval of teplizumab represents a fundamental change: it is the first non-insulin therapy to address the underlying immune process that drives Type 1 diabetes. This opening has sparked momentum for additional immunotherapies in development, with numerous trials now underway across the research community.

Researchers are actively testing new immunotherapies through several major research networks, including TrialNet and the Immune Tolerance Network (ITN). These trials are exploring two key areas: prevention (in people at high risk who don't yet have diabetes) and recent-onset (in people newly diagnosed with Type 1 diabetes).

Current prevention trials include studies of ATG (antithymocyte globulin), with additional trials opening soon. For recently diagnosed patients, the ATD trials are underway in adults, with plans to expand into pediatric populations once initial safety and efficacy data are collected in the adult population. This phased approach allows researchers to build evidence carefully before broadening access to younger age groups.

The emergence of immunotherapies marks a turning point in Type 1 diabetes research. For the first time, treatment options are moving beyond insulin management to address the immune dysfunction at the root of the disease. While these therapies are not cures, they offer a new avenue for potentially altering the disease course.

For those interested in participating in research, active trials through TrialNet and other networks may provide opportunities to access investigational treatments while contributing to the scientific understanding of Type 1 diabetes. Anyone considering clinical trial participation should speak with their healthcare provider about eligibility and what involvement might mean for their individual situation.

Origin: YouTube / WebsEdgeMedicine (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.